Research Options:
Week of Expected Pricing Withdrawn
Company Name Audeo oncology, Inc.
Proposed Ticker AURX
CUSIP 05070L107
Business Description A late stage biopharmaceutical company primarily focused on utilizing our Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity.
Lead Underwriter Leerink Swann LLC, Oppenheimer and Co., Inc.
Co-Managers N/A
Initial Shares 3,250,000
Revised Initial Shares N/A
Initial Price $14.00-$16.00
Revised Price N/A
Final Price N/A
Final Ticker N/A

 

 
   
  © 2024 ICE Data Services. All rights reserved.